Gamabufotalin Inhibits the Proliferation of Triple Negative Breast Cancer Cells Through HSP90/mutant p53 Pathway

XIAO Pei, LI Meiling, ZHOU Jianlin, ZHOU Chang

PDF(1660 KB)
PDF(1660 KB)
Life Science Research ›› 2023, Vol. 27 ›› Issue (3) : 217-222.

Gamabufotalin Inhibits the Proliferation of Triple Negative Breast Cancer Cells Through HSP90/mutant p53 Pathway

  • XIAO Pei, LI Meiling, ZHOU Jianlin, ZHOU Chang
Author information +
History +

Abstract

Triple negative breast cancer (TNBC) is a highly malignant tumor with a poor prognosis, and the mutation frequency of p53 gene in TNBC patients is more than 80%. Gamabufotalin (CS-6), a skin secretion from Japanese common toad (Bufo japonicus), has been shown to have anticancer effects. However, the role and underlying mechanism of CS-6 against TNBC have not been reported. Herein, the effects of different concentrations of CS-6 on the proliferation of TNBC cell lines MDA-MB-468 and MDA-MB-231 were de-tected by MTT assay and clone formation assay. The effects of CS-6 on the expression of p53 and heat shock protein 90 (HSP90) at exogenous and endogenous levels were detected by Western-blot. The synergistic effect of CS-6 and the HSP90 inhibitor tanespimycin (17-AAG) on the proliferation of MDA-MB-468 and MDA-MB-231 cells was investigated by combination index and equivalent linearization analysis. The results showed that CS-6 significantly inhibited the proliferation of MDA-MB-468 and MDA-MB-231 cells. The mechanism of inhibition of the tumor cell proliferation may be related to degradation of HSP90/mutant p53 protein. In addition, CS-6 and HSP90 inhibitor 17-AAG had a synergistic inhibitory effect on the prolifera-tion of MDA-MB-468 and MDA-MB-231 cells.

Key words

gamabufotalin (CS-6) / triple negative breast cancer (TNBC) / p53 protein / heat shock protein 90 (HSP90) / drug combination

Cite this article

Download Citations
XIAO Pei, LI Meiling, ZHOU Jianlin, ZHOU Chang. Gamabufotalin Inhibits the Proliferation of Triple Negative Breast Cancer Cells Through HSP90/mutant p53 Pathway. Life Science Research. 2023, 27(3): 217-222

Comments

PDF(1660 KB)

Accesses

Citation

Detail

Sections
Recommended

/